Celldex Therapeutics (CLDX) Cash from Operations (2010 - 2026)

Celldex Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 65600000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 20.65% year-over-year to 65600000.0; the TTM figure through Mar 2026 stood at 222173000.0 (down 29.54% YoY), while the FY2025 annual figure was 210945000.0, down 33.7% from the prior year.
• Cash from Operations was 65600000.0 for Q1 2026 at Celldex Therapeutics, down from 63940000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 18993000.0 in Q3 2023 to a low of 65600000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 37961529.41 across 5 years, with a median of 32533000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations soared 46.03% in 2023, then slumped 191.35% in 2024.
• A 5-year view of Cash from Operations shows it stood at 21762000.0 in 2022, then sank by 49.49% to 32533000.0 in 2023, then climbed by 0.18% to 32476000.0 in 2024, then slumped by 96.88% to 63940000.0 in 2025, then decreased by 2.6% to 65600000.0 in 2026.
• The last three Cash from Operations figures came in at 65600000.0 (Q1 2026), 63940000.0 (Q4 2025), and 48605000.0 (Q3 2025), per Business Quant data.